

## SHCP APC Summary

### Date: September 2024

Link to the previous SHCP APC minutes are available [HERE](#)

SHCP APC item	Summary of decision
<b>Dexcom One +</b> - new medicine application	<b>Approved</b> with a <b>PURPLE (specialist initiation with supply of two sensors)</b> for people living with Type 1 diabetes formulary coding. Dexcom ONE is being phased out and will cease to be available in May 2025, patients currently prescribed Dexcom ONE to be offered to change to Dexcom ONE+ at their next routine appointment.
<b>Nutriprem Human Milk Fortifier</b> - new medicine application	<b>Approved</b> with a <b>PURPLE (specialist initiation with two week's supply)</b> formulary coding to be used for premature infants who are breast fed but require additional nutrients for weight gain and growth for a maximum total treatment time of 10 months
<b>Nifedipine immediate release (IR) capsules</b> - colour status change application	<b>Approved</b> with a <b>PURPLE (recommendation without supply)</b> for Raynaud's syndrome, second line to Modified Release (MR) if MR is clinically inappropriate or not tolerated.
<b>Type 2 Diabetes Treatment Algorithm (updated)</b>	<b>Approved</b> <a href="https://int.sussex.ics.nhs.uk/clinical_documents/diabetes-management-of-type-2-diabetes-in-adults/">int.sussex.ics.nhs.uk/clinical_documents/diabetes-management-of-type-2-diabetes-in-adults/</a>
<b>Chronic Kidney Disease (CKD) guideline (updated)</b>  And  <b>CKD Frequently Asked Questions document</b>	<b>Approved</b> <a href="https://int.sussex.ics.nhs.uk/clinical_documents/chronic-kidney-disease-treatment-algorithm-for-adults/">int.sussex.ics.nhs.uk/clinical_documents/chronic-kidney-disease-treatment-algorithm-for-adults/</a>  <b>Approved</b> <a href="https://int.sussex.ics.nhs.uk/clinical_documents/chronic-kidney-disease-faq/">int.sussex.ics.nhs.uk/clinical_documents/chronic-kidney-disease-faq/</a>
<b>Finerenone 10mg/20mg tablets</b> - colour status change application	<b>Approved</b> with a <b>GREEN</b> formulary coding.
<b>Ivermectin 3mg tablets</b> – new medicine application	<b>Approved</b> with a <b>GREEN</b> formulary coding 3 <sup>rd</sup> line for scabies if topical treatments have failed or are unavailable.
<b>FreeStyle Libre 2 Plus Continuous Glucose Sensor</b> - new medicine application	<b>Approved</b> with a <b>PURPLE (recommendation without supply)</b> for patient living with Type 1 diabetes as part of their hybrid closed loop pump system.
<b>SHCP APC item</b>	<b>Virtually approved</b>
<b>Valproate Shared Care Protocol (updated)</b>	<b>Approved</b> 09.09.2024 <b>Available to download</b> <a href="#">Shared care - Sussex Health &amp; Care (ics.nhs.uk)</a>

<b>Mycophenolate and Mycophenolic acid Shared Care Protocol in adult services (for non-transplant indications) in Sussex</b>	<b>Approved</b> 20.09.2024 <b>Available to download</b> <a href="#">Shared care - Sussex Health &amp; Care (ics.nhs.uk)</a>
<b>Mycophenolic acid tablets- colour status change application</b>	<b>Approved</b> with an <b>AMBER</b> formulary coding 20.09.2024
<b>Riluzole Shared Care Protocol</b>	<b>Approved</b> 20.09.2024 <b>Available to download</b> <a href="#">Shared care - Sussex Health &amp; Care (ics.nhs.uk)</a>
<b>Riluzole 50mg orodispersible films (Emylif®) - formulary extension application</b>	<b>Approved</b> with an <b>AMBER</b> formulary coding 20.09.2024
<b>Sativex Shared Care Protocol</b>	<b>Approved</b> 20.09.2024 <b>Available to download</b> <a href="#">Shared care - Sussex Health &amp; Care (ics.nhs.uk)</a>
<b>Vitamin D management guidelines for adults and children (updated)</b>	<b>Approved</b> 20.09.2024 <a href="http://int.sussex.ics.nhs.uk/clinical_documents/vitamin-d-management-in-adults/">int.sussex.ics.nhs.uk/clinical_documents/vitamin-d-management-in-adults/</a>  <a href="http://int.sussex.ics.nhs.uk/clinical_documents/vitamin-d-management-in-children/">int.sussex.ics.nhs.uk/clinical_documents/vitamin-d-management-in-children/</a>
<b>Colecalciferol 1000-unit tablets - formulary extension application</b>	<b>Approved</b> with a <b>GREEN</b> formulary coding
<b>NICE Technology Appraisals</b>	
<b>NICE TA688</b> Selective internal radiation therapies for treating hepatocellular carcinoma	<b>Approved</b> <b>RED</b> formulary coding
<b>NICE TA985</b> Selective internal radiation therapy with <b>QuiremSpheres</b> for treating unresectable advanced hepatocellular carcinoma	<b>Approved</b> <b>RED</b> formulary coding
<b>NICE TA986</b> <b>Lebrikizumab</b> for treating moderate to severe atopic dermatitis in people 12 years and over	<b>Approved</b> <b>RED</b> formulary coding
<b>NICE TA988</b> <b>Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor</b> for treating cystic fibrosis	<b>Approved</b> <b>RED</b> formulary coding
<b>NICE TA989</b> <b>Etranacogene dezaparvovec</b> for treating moderately severe or severe haemophilia B	<b>Approved</b> <b>RED</b> formulary coding
<b>NICE TA990</b> <b>Tenecteplase</b> for treating acute ischaemic stroke	<b>Approved</b> <b>RED</b> formulary coding
<b>NICE TA991</b> <b>Abaloparatide</b> for treating osteoporosis after menopause	<b>Approved</b> <b>RED</b> formulary coding

<b>NICE TA992 Trastuzumab deruxtecan</b> for treating HER2-low metastatic or unresectable breast cancer after chemotherapy	<b>Approved RED</b> formulary coding
<b>NICE TA993 Burosumab</b> for treating X-linked hypophosphataemia in adults	<b>Approved RED</b> formulary coding
<b>NICE TA995 Relugolix</b> for treating hormone-sensitive prostate cancer	<b>Approved PURPLE</b> formulary coding
<b>NICE TA996 Linzagolix</b> for treating moderate to severe symptoms of uterine fibroids	<b>Approved PURPLE</b> formulary coding
<b>NICE TA997 Pembrolizumab with platinum- and fluoropyrimidine-based</b> chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma	<b>Approved RED</b> formulary coding
<b>NICE TA998 Risankizumab</b> for treating moderately to severely active ulcerative colitis	<b>Approved RED</b> formulary coding
<b>NICE Guidelines</b>	
<b>NG242 Diabetic retinopathy:</b> management and monitoring	Reviewed by ICB Therapeutic Leads and confirmed all local prescribing positions are compliant.
<b>NG243 Adrenal insufficiency:</b> identification and management	Reviewed by ICB Therapeutic Leads and confirmed all local prescribing positions are compliant.
<b>Discontinuations</b>	
<b>Hyrimoz (adalimumab)</b> 40mg/0.8ml and 40mg/0.4ml solution for injection pre-filled pens AND Hyrimoz (adalimumab) 40mg/0.8ml solution for injection pre-filled syringes	21 <sup>st</sup> May 2024
<b>Interferon beta-1b</b> 300microgram powder and solvent for solution for injection vials	24 <sup>th</sup> May 2024
<b>Somatropin (NutropinAq)</b> 10mg/2ml solution for injection cartridges and <b>Somatropin (Humatrope)</b> 6mg, 12mg and 24mg powder and solvent for solution for injection cartridges	26 <sup>th</sup> April 2024
<b>Tacalcitol</b> topical preparations	31 <sup>st</sup> July 2024
<b>Nortriptyline</b> oral solution sugar-free	28 <sup>th</sup> May 2024
<b>Menopur (menotropin)</b> 150IU solution for injection vials	10 <sup>th</sup> July 2024